Tech Company Financing Transactions
Rona Therapeutics Funding Round
Rona Therapeutics closed a $35 million Series A funding round on 7/19/2024. Investors included Long River Investments and private investors.
Transaction Overview
Company Name
Announced On
7/19/2024
Transaction Type
Venture Equity
Amount
$35,000,000
Round
Series A
Investors
Long River Investments (Lead Investor)
Proceeds Purpose
The company intends to use the funds to progress metabolic siRNA pipeline programs into global development and expand extra-hepatic delivery platform in CNS and beyond.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
Tower 3, JNB Life Science Park, No.795, Kangwei Road, Pudong
Shanghai, Undisclosed
China
Shanghai, Undisclosed
China
Phone
Undisclosed
Website
Email Address
Overview
Rona Therapeutics is a world leading nucleic acid therapeutics company dedicated to addressing metabolic and degenerative diseases. Inceptioned in 2021, Rona Therapeutics has advanced several best-in-class siRNA therapeutics in the clinic or IND enabling stage, including PCSK9 siRNA for hypercholesteremia and APOC3 siRNA for mixed dyslipidemia.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Stella Shi
Chief Medical Officer
Hongmei Li
Vice President
Jianwu Fang
Vice President
Jinyu Huang
VP - Administration
Jasper Tu
VP - Operations
Runhan Gao
VP - R & D
Ling Pan
Browse more venture capital transactions:
Prev: 7/19/2024: Bionic Power venture capital transaction
Next: 7/19/2024: Aereo venture capital transaction
Share this article
About Our VC Transactions Data
Our team works diligently to document every notable VC transaction. VC investment data records on this site come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs